Literature DB >> 33784560

Role of TRPM7 kinase in cancer.

Selena Meng1, Rahmah Alanazi1, Delphine Ji1, Julia Bandura2, Zheng-Wei Luo1, Andrea Fleig3, Zhong-Ping Feng4, Hong-Shuo Sun5.   

Abstract

Cancer is the second leading cause of death worldwide and accounted for an estimated 9.6 million deaths, or 1 in 6 deaths, in 2018. Despite recent advances in cancer prevention, diagnosis, and treatment strategies, the burden of this disease continues to grow with each year, with dire physical, emotional, and economic consequences for all levels of society. Classic characteristics of cancer include rapid, uncontrolled cell proliferation and spread of cancerous cells to other parts of the body, a process known as metastasis. Transient receptor potential melastatin 7 (TRPM7), a Ca2+- and Mg2+-permeable nonselective divalent cation channel defined by the atypical presence of an α-kinase within its C-terminal domain, has been implicated, due to its modulation of Ca2+ and Mg2+ influx, in a wide variety of physiological and pathological processes, including cancer. TRPM7 is overexpressed in several cancer types and has been shown to variably increase cellular proliferation, migration, and invasion of tumour cells. However, the relative contribution of TRPM7 kinase domain activity to cancer as opposed to ion flux through its channel pore remains an area of active discovery. In this review, we describe the specific role of the TRPM7 kinase domain in cancer processes as well as mechanisms of regulation and inhibition of the kinase domain.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Inhibitor; Ion channels; TRPM7; TRPM7 kinase; Tumor

Mesh:

Substances:

Year:  2021        PMID: 33784560     DOI: 10.1016/j.ceca.2021.102400

Source DB:  PubMed          Journal:  Cell Calcium        ISSN: 0143-4160            Impact factor:   6.817


  4 in total

1.  Increased Wnt/β-catenin signaling contributes to autophagy inhibition resulting from a dietary magnesium deficiency in injury-induced osteoarthritis.

Authors:  Ruijun Bai; Michael Z Miao; Hui Li; Yiqing Wang; Ruixue Hou; Ke He; Xuan Wu; Hongyu Jin; Chao Zeng; Yang Cui; Guanghua Lei
Journal:  Arthritis Res Ther       Date:  2022-07-08       Impact factor: 5.606

2.  TRPM7 Modulates Human Pancreatic Stellate Cell Activation.

Authors:  Julie Auwercx; Philippe Kischel; Thibaut Lefebvre; Nicolas Jonckheere; Alison Vanlaeys; Stéphanie Guénin; Silviya Radoslavova; Isabelle Van Seuningen; Halima Ouadid-Ahidouch; Hemant M Kocher; Isabelle Dhennin-Duthille; Mathieu Gautier
Journal:  Cells       Date:  2022-07-21       Impact factor: 7.666

3.  Promoter methylation of transient receptor potential melastatin-related 7 (TRPM7) predicts a better prognosis in patients with Luminal A breast cancers.

Authors:  Yuanyuan Wang; Rong Lu; Pu Chen; Rongrong Cui; Meiju Ji; Xiaozhi Zhang; Peng Hou; Yiping Qu
Journal:  BMC Cancer       Date:  2022-09-05       Impact factor: 4.638

4.  Canine Oral Melanoma Genomic and Transcriptomic Study Defines Two Molecular Subgroups with Different Therapeutical Targets.

Authors:  Anais Prouteau; Stephanie Mottier; Aline Primot; Edouard Cadieu; Laura Bachelot; Nadine Botherel; Florian Cabillic; Armel Houel; Laurence Cornevin; Camille Kergal; Sébastien Corre; Jérôme Abadie; Christophe Hitte; David Gilot; Kerstin Lindblad-Toh; Catherine André; Thomas Derrien; Benoit Hedan
Journal:  Cancers (Basel)       Date:  2022-01-06       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.